Kong Yuan, Wang Ya-Zhe, Hu Yue, Huang Xiao-Jun
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China.
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China; Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):73-7. doi: 10.7534/j.issn.1009-2137.2014.01.016.
The purpose of this study was to establish a novel xenotransplant mouse model with human Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL). The bone marrow mononuclear cells (BMMNC) were separated from newly diagnosed Ph(+)ALL patients, and injected into 2.1 Gy of (60)Co irradiated and anti-CD122-conditioned NOD/SCID mice through intra femoral injection. Human hematopoietic chimerism in bone marrow and spleen of the recipients was detected by flow cytometry. Morphological analysis of murine marrow cells were performed using May-Giemsa staining. BCR/ABL1 level was detected by RQ-PCR and FISH assays. Furthermore, leukemia infiltration in the organs was evaluated by hematoxylin-eosin staining, immunohistochemical staining with anti-human CD19 and anti-human CD34 antibodies. The results indicated that the unsorted BMMNC from Ph(+)ALL patients were able to repopulate human Ph(+)ALL in vivo. The percentages of human CD45(+)CD19(+) cells in bone marrow, and spleen of the recipient mice were 87.2% ± 10.1% and 79.9% ± 9.2%, respectively. Furthermore, the engrafted cells possessed same morphology, phenotypic and cytogenetic characteristics as cells from the original Ph(+)ALL patients. Compatible with the clinical features, transplanted Ph(+)ALL cells infiltrated into the brain, liver, and kidney of the recipients. It is concluded that the human-mouse xenotransplant established model using intra femoral injection of an anti-CD122-conditioned NOD/SCID repopulation may provide a promising system to study the biology of human Ph(+)ALL in vivo.
本研究的目的是建立一种携带人类费城染色体阳性急性淋巴细胞白血病(Ph(+)ALL)的新型异种移植小鼠模型。从新诊断的Ph(+)ALL患者中分离出骨髓单个核细胞(BMMNC),通过股内注射将其注入经2.1 Gy (60)Co照射并经抗CD122预处理的NOD/SCID小鼠体内。通过流式细胞术检测受体骨髓和脾脏中的人类造血嵌合体。使用May-Giemsa染色对小鼠骨髓细胞进行形态学分析。通过RQ-PCR和FISH检测BCR/ABL1水平。此外,通过苏木精-伊红染色、抗人CD19和抗人CD34抗体的免疫组织化学染色评估器官中的白血病浸润情况。结果表明,来自Ph(+)ALL患者的未分选BMMNC能够在体内重建人类Ph(+)ALL。受体小鼠骨髓和脾脏中人类CD45(+)CD19(+)细胞的百分比分别为87.2%±10.1%和79.9%±9.2%。此外,植入的细胞具有与原始Ph(+)ALL患者细胞相同的形态、表型和细胞遗传学特征。与临床特征相符,移植的Ph(+)ALL细胞浸润到受体的脑、肝和肾中。结论是,使用股内注射抗CD122预处理的NOD/SCID重建的人-小鼠异种移植模型可能为体内研究人类Ph(+)ALL的生物学特性提供一个有前景的系统。